HitGen and Almirall Announce Achievement of Milestone in Their Strategic Collaboration
Summary
The licensed compounds were identified using HitGen’s leading technology platform, which involved screening large DNA encoded libraries, containing more than 500 billion of small molecules with drug-like properties synthesized on chemically diverse scaffolds. We look forward to seeing the further progress made by Almirall for their innovative research programs to address unmet medical needs,” said Dr. Jin Li, Chairman of the Board and Chief Executive Officer of HitGen. Bhushan Hardas, M.D., MBA, Chief Scientific Officer of Almirall, commented that “We are thrilled to have achieved success at a fast pace in this strategic collaboration with HitGen’s platform to discover novel small molecules in a challenging target. These compounds are members of DELs synthesised from many hundreds of distinct chemical scaffolds, designed and assembled with tractable chemistry based on proven results for identifying drug-like leads against biological targets from known and novel classes. HitGen is working with multiple pharmaceutical and biotech companies, foundations and research institutes in North America, Europe and Asia to discover and develop novel therapeutics of the future.
Classifications
AskAI Classifications
LabelsLinked Companies
